ALKEM.NS Balance Sheet
Alkem Laboratories Ltd.
Profit & Loss Balance Sheet Cash Flow
Balance Sheet · 4 years on file
(FY2022-23 to FY2025-26)
· fetched 2026-08-23 21:34
| Line item | FY2022-23 | FY2023-24 | FY2024-25 | FY2025-26 | Source (XBRL element) |
|---|---|---|---|---|---|
| Property, Plant and Equipment | ₹2,065.40 Cr. | ₹2,161.46 Cr. | ₹2,063.93 Cr. | ₹2,694.97 Cr. | PropertyPlantAndEquipment |
| Capital Work-in-Progress | ₹310.27 Cr. | ₹148.40 Cr. | ₹476.55 Cr. | ₹137.91 Cr. | CapitalWorkInProgress |
| Goodwill | ₹413.17 Cr. | ₹416.74 Cr. | ₹423.11 Cr. | ₹523.64 Cr. | Goodwill |
| Other Intangible Assets | ₹204.28 Cr. | ₹294.58 Cr. | ₹365.27 Cr. | ₹652.42 Cr. | OtherIntangibleAssets |
| Non-current Investments | ₹304.61 Cr. | ₹334.80 Cr. | ₹943.24 Cr. | ₹1,131.50 Cr. | NoncurrentInvestments |
| Other Non-current Assets | ₹110.50 Cr. | ₹162.12 Cr. | ₹188.05 Cr. | ₹343.04 Cr. | OtherNoncurrentAssets |
| Total Non-current Assets | ₹5,026.97 Cr. | ₹5,163.32 Cr. | ₹6,745.28 Cr. | ₹8,662.45 Cr. | NoncurrentAssets |
| Inventories | ₹2,607.53 Cr. | ₹2,661.18 Cr. | ₹2,922.41 Cr. | ₹3,333.22 Cr. | Inventories |
| Trade Receivables | ₹2,132.18 Cr. | ₹2,252.81 Cr. | ₹2,466.25 Cr. | ₹2,979.11 Cr. | TradeReceivablesCurrent |
| Cash and Cash Equivalents | ₹273.80 Cr. | ₹455.07 Cr. | ₹304.14 Cr. | ₹247.91 Cr. | CashAndCashEquivalents |
| Current Investments | ₹317.21 Cr. | ₹148.99 Cr. | ₹902.26 Cr. | ₹737.31 Cr. | CurrentInvestments |
| Other Current Assets | ₹736.09 Cr. | ₹829.98 Cr. | ₹832.67 Cr. | ₹898.83 Cr. | OtherCurrentAssets |
| Total Current Assets | ₹8,606.42 Cr. | ₹10,411.58 Cr. | ₹10,811.19 Cr. | ₹12,210.52 Cr. | CurrentAssets |
| Total Assets | ₹13,756.65 Cr. | ₹15,574.90 Cr. | ₹17,691.10 Cr. | ₹20,872.97 Cr. | Assets |
| Equity Share Capital | ₹23.91 Cr. | ₹23.91 Cr. | ₹23.91 Cr. | ₹23.91 Cr. | EquityShareCapital |
| Other Equity | ₹9,021.38 Cr. | ₹10,288.15 Cr. | ₹11,960.96 Cr. | ₹13,796.19 Cr. | OtherEquity |
| Equity Attributable to Owners | ₹9,045.29 Cr. | ₹10,312.06 Cr. | ₹11,984.87 Cr. | ₹13,820.10 Cr. | EquityAttributableToOwnersOfParent |
| Non-controlling Interests | ₹389.71 Cr. | ₹402.34 Cr. | ₹448.76 Cr. | ₹528.83 Cr. | NonControllingInterest |
| Total Equity | ₹9,435.00 Cr. | ₹10,714.40 Cr. | ₹12,433.63 Cr. | ₹14,348.93 Cr. | Equity |
| Long-term Borrowings | ₹70.33 Cr. | ₹40.00 Cr. | ₹310.91 Cr. | ₹492.45 Cr. | BorrowingsNoncurrent |
| Total Non-current Liabilities | ₹614.50 Cr. | ₹865.95 Cr. | ₹1,292.49 Cr. | ₹1,741.34 Cr. | NoncurrentLiabilities |
| Short-term Borrowings | ₹1,326.35 Cr. | ₹1,173.97 Cr. | ₹751.88 Cr. | ₹1,131.05 Cr. | BorrowingsCurrent |
| Trade Payables | ₹1,165.03 Cr. | ₹1,748.12 Cr. | ₹1,839.35 Cr. | ₹2,244.18 Cr. | TradePayablesCurrent |
| Other Current Liabilities | ₹186.89 Cr. | ₹229.65 Cr. | ₹305.70 Cr. | ₹319.17 Cr. | OtherCurrentLiabilities |
| Total Current Liabilities | ₹3,707.15 Cr. | ₹3,994.55 Cr. | ₹3,958.69 Cr. | ₹4,782.70 Cr. | CurrentLiabilities |
| Total Equity and Liabilities | ₹13,756.65 Cr. | ₹15,574.90 Cr. | ₹17,691.10 Cr. | ₹20,872.97 Cr. | EquityAndLiabilities |
Every figure above is the exact value of the named XBRL element from ALKEM.NS's cached filing for that year — nothing here is estimated or backfilled. A company shows one column per year StockProof actually has data for — never padded with blank years. Rows shown as N/A are genuinely not disclosed under that year's filing format (see peer comparison for how other Healthcare companies compare).